Nevada-based health tech company, Kleiner Device Labs (KDL) announced that it will host a meeting room at McKinsey & Company’s Early Stage Investor Conference on the morning of Wednesday, June 22 as part of the event’s HealthTech track. Investors interested in talking with KDL may find more information and registration at McKinsey’s conference web site.
Top Big Data News: OpenText Powers the Information Advantage with Cloud Editions 22.2
“We are excited to participate in McKinsey & Company’s conference to meet prospective investors for future funding opportunities,” said KDL’s founder and CEO, Jeff Kleiner MD.
Last year, KDLhad announced that it received U.S. Food and Drug Administration (FDA) 510(k) market clearance for its KG™2 Surge™ flow-thru interbody system
KDL is in the midst of launching its next product, the KG2TM SurgeTM flow-thru interbody system, which employs the company’s proprietary flow-thru technology to streamline the implant delivery, positioning and grafting processes for TLIF and PLIF spinal fusion procedures. This brings important outcome and cost improvements to spinal fusion surgeries.
Top AITHORITY News: Grayshift Announces Strategic Investment from Thoma Bravo
Kleiner Device Labs is creating new instruments and devices to advance minimally invasive spine surgery and improve outcomes and costs. Kleiner Device Labs is headquartered in Incline Village, Nevada.
Comments are closed.